Affimed provides data update of AFM13 in combination with Keytruda® in patients with relapsed/refractory Hodgkin Lymphoma and informs about future development plans for AFM13
Adi Hoess, CEO Leila Alland, CMO
Stockholm, Sweden
June 15, 2018
8:30 am ET
6246081
Denmark: +45 35 15 80 49
France: +33 (0)1 70 72 25 50
Germany: +49 (0)69 2222 25574
Netherlands: +31 (0) 20 703 8211
Switzerland: +41 (0)22 567 5729
United Kingdom: +44 (0)330 336 9125
United States: +1 929-477-0448